Shots:
In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Perjeta and prepared a curated analysis report for our readers
Perjeta is indicated for the treatment of HER2-positive metastatic breast cancer, neoadjuvant HER2-positive breast cancer, Adjuvant HER2-positive breast cancer
PharmaShots presents a concise…
Shots:
David Domzalski, President & Chief Executive Officer at VYNE Therapeutics, in an invigorating conversation with PharmaShots
The PIPE transaction generated $88M ensuring a steady cash flow through the end of 2025 and multiple anticipated clinical catalysts across VYNE’s BET inhibitor platform
David believes the financing will be instrumental in the advancement of VYN201, into…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EC, and China’s NMPA. This month’s report includes 6 biological drugs, 10 small molecules, 5 cell and gene therapies, 1 recombinant fusion protein, 1 peptide and 2 devices
Neurocrine Biosciences’ Crinecerfont, focused on the treatment of Congenital Adrenal Hyperplasia…
PharmaShots Magazine's first edition of 2024 is out. Our Jan'24 theme is India’s Role in Global Healthcare! With a market size of $280B in 2020, India is swiftly emerging as a key player in the global healthcare arena. This month's magazine delve into some compelling insights that underscore India's pivotal role in shaping the future…
Gear up for the most awaited metaverse-based global event!
Don’t miss out on this enlightening conference focussed on Oncology domains by Ingenious E-Brain.
The virtual event “e-Brain OncoVision: Connecting the Dots in Cancer Care” is scheduled for February 15th (9:00AM EST) to February 16th, 2024 (5:30PM EST)
Featuring renowned speakers from leading biopharma companies & organizations, the…
Shots:
The Fourth quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, BMS acquired Mirati Therapeutics for ~$5.8B and AbbVie acquired ImmunoGen for $10.1B
The Fourth quarter of the year also showcases multiple clinical trial results from Regeneron’s Two-Year…
Shots:
Exemplifying awareness campaign at its best with a hint of contemporary music, “It takes 2” by Boehringer Ingelheim and Eli Lilly is a noble initiative aimed at integrating UACR testing with eGFR for better screening of CKD
Noelle Bush, in an engaging conversation with PharmaShots, cites the growing incidences of CKD in the US.…
Shots:
In the next installment of Dealmaker 2023, we bring an informative report on the Top M&A based on the Deal Value
The report revolves around Pfizer, which signed 16 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases that have summed to a total of $63.23B
Propelled by the invaluable…
In pursuit of achieving data-driven excellence, PharmaShots came across Newstex. Soon, as a part of a collaboration PharmaShots and Newstex embarked on a journey to delivering high-quality and unerring content. Himanshu Sehgal, Director at PharmaShots, in a candid conversation with Newstex’s Head of Publisher Solutions, Laura Acosta. While sharing the origin story of PharmaShots, Himanshu…
Shots:
The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved
For the January edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Glioblastoma, the most…

